GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Piotroski F-Score

Boston Scientific (Boston Scientific) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 1992. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boston Scientific has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Boston Scientific's Piotroski F-Score or its related term are showing as below:

BSX' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Boston Scientific was 7. The lowest was 4. And the median was 6.


Boston Scientific Piotroski F-Score Historical Data

The historical data trend for Boston Scientific's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 7.00 6.00 7.00

Boston Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 6.00 7.00 7.00

Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 314 + 270 + 504 + 505 = $1,593 Mil.
Cash Flow from Operations was 190 + 658 + 698 + 957 = $2,503 Mil.
Revenue was 3389 + 3599 + 3527 + 3725 = $14,240 Mil.
Gross Profit was 2349 + 2529 + 2426 + 2578 = $9,882 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(32469 + 32892 + 33601 + 34043 + 35136) / 5 = $33628.2 Mil.
Total Assets at the begining of this year (Dec22) was $32,469 Mil.
Long-Term Debt & Capital Lease Obligation was $8,961 Mil.
Total Current Assets was $6,514 Mil.
Total Current Liabilities was $4,933 Mil.
Net Income was 110 + 260 + 188 + 140 = $698 Mil.

Revenue was 3026 + 3244 + 3170 + 3242 = $12,682 Mil.
Gross Profit was 2071 + 2222 + 2191 + 2231 = $8,715 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(32229 + 32337 + 32189 + 31947 + 32469) / 5 = $32234.2 Mil.
Total Assets at the begining of last year (Dec21) was $32,229 Mil.
Long-Term Debt & Capital Lease Obligation was $9,262 Mil.
Total Current Assets was $5,760 Mil.
Total Current Liabilities was $3,803 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boston Scientific's current Net Income (TTM) was 1,593. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boston Scientific's current Cash Flow from Operations (TTM) was 2,503. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=1593/32469
=0.04906218

ROA (Last Year)=Net Income/Total Assets (Dec21)
=698/32229
=0.02165751

Boston Scientific's return on assets of this year was 0.04906218. Boston Scientific's return on assets of last year was 0.02165751. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Boston Scientific's current Net Income (TTM) was 1,593. Boston Scientific's current Cash Flow from Operations (TTM) was 2,503. ==> 2,503 > 1,593 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=8961/33628.2
=0.26647278

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=9262/32234.2
=0.28733457

Boston Scientific's gearing of this year was 0.26647278. Boston Scientific's gearing of last year was 0.28733457. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=6514/4933
=1.32049463

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=5760/3803
=1.51459374

Boston Scientific's current ratio of this year was 1.32049463. Boston Scientific's current ratio of last year was 1.51459374. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Boston Scientific's number of shares in issue this year was 1476.7. Boston Scientific's number of shares in issue last year was 1442.7. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9882/14240
=0.69396067

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=8715/12682
=0.68719445

Boston Scientific's gross margin of this year was 0.69396067. Boston Scientific's gross margin of last year was 0.68719445. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=14240/32469
=0.43857218

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=12682/32229
=0.39349654

Boston Scientific's asset turnover of this year was 0.43857218. Boston Scientific's asset turnover of last year was 0.39349654. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boston Scientific has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Boston Scientific  (NYSE:BSX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Boston Scientific Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (Boston Scientific) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Joseph Michael Fitzgerald officer: SVP & President, Endovascular C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss officer: SVP&Pres, Periph Intervent C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Wendy Carruthers officer: SVP, Human Resources C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Arthur C Butcher officer: SVP&Pres, Endoscopy C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney officer: President BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Vance R Brown officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Thepaut Eric Francis Yves officer: SVP & Pres, Europe C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
John Bradley Sorenson officer: SVP, Glob Ops & Qual C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jonathan Monson officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Daniel J. Brennan officer: EVP and CFO BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Nelda J Connors director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Scott Olson officer: SVP & Pres, Rhythm Management C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752